Näytä suppeat kuvailutiedot

dc.contributor.authorVia, Jack Dalla
dc.contributor.authorDaly, Robin M.
dc.contributor.authorOwen, Patrick J.
dc.contributor.authorMundell, Niamh L.
dc.contributor.authorRantalainen, Timo
dc.contributor.authorFraser, Steve F.
dc.date.accessioned2019-07-17T06:36:02Z
dc.date.available2020-10-01T21:35:10Z
dc.date.issued2019
dc.identifier.citationVia, J. D., Daly, R. M., Owen, P. J., Mundell, N. L., Rantalainen, T., & Fraser, S. F. (2019). Bone mineral density, structure, distribution and strength in men with prostate cancer treated with androgen deprivation therapy. <i>Bone</i>, <i>127</i>, 367-375. <a href="https://doi.org/10.1016/j.bone.2019.06.005" target="_blank">https://doi.org/10.1016/j.bone.2019.06.005</a>
dc.identifier.otherCONVID_30939592
dc.identifier.urihttps://jyx.jyu.fi/handle/123456789/65073
dc.description.abstractAndrogen deprivation therapy (ADT) improves survival in men with advanced prostate cancer (PCa), but has been associated with compromised skeletal health and increased fracture risk. However, limited previous research has investigated determinants of bone strength beyond DXA-derived areal bone mineral density (aBMD) in this population group. The aim of this cross-sectional study was to investigate the effects of ADT in men with PCa on BMD, bone structure, estimates of whole bone strength and cortical bone distribution. A total of 70 ADT-treated men, 52 PCa controls and 70 healthy controls had DXA lumbar spine and proximal femur aBMD and pQCT distal (4%) and proximal (66%) tibia and radius cortical and trabecular volumetric BMD (vBMD), bone structure, strength and cortical bone distribution assessed. Analyses included BMI and/or tibia/radius length as covariates. On average, ADT-treated men had a higher BMI than PCa (P < 0.05) but not healthy controls. ADT-treated men had 7.2–7.8% lower lumbar spine aBMD than PCa (P = 0.037) and healthy controls (P = 0.010), with a trend for a lower total hip aBMD in the ADT-treated men (P = 0.07). At the distal tibia, total bone area was 6.2–7.3% greater in ADT-treated men than both controls (P < 0.01), but total vBMD was 8.4–8.7% lower in ADT-treated men than both controls (P < 0.01). Moreover, bone strength index (BSI) was 10.8% lower relative to healthy controls only (P < 0.05). At the distal radius, ADT-treated men had lower total and trabecular vBMD (10.7–14.8%, P < 0.05) and BSI (23.6–27.5%, P < 0.001) compared to both controls. There were no other differences in bone outcomes at the proximal tibia or radius. In conclusion, ADT treatment for PCa was associated with lower BMD and estimated compressive bone strength, particularly at trabecular skeletal sites (lumbar spine, and distal tibia and radius), compared to controls, but there were no consistent differences in cortical bone structure, distribution or bending strength.fi
dc.format.mimetypeapplication/pdf
dc.language.isoeng
dc.publisherElsevier Inc.
dc.relation.ispartofseriesBone
dc.rightsCC BY-NC-ND 4.0
dc.subject.otherandrogen deprivation therapy
dc.subject.otherbone mineral density
dc.subject.otherbone strength
dc.subject.otherbone distribution
dc.titleBone mineral density, structure, distribution and strength in men with prostate cancer treated with androgen deprivation therapy
dc.typeresearch article
dc.identifier.urnURN:NBN:fi:jyu-201907163638
dc.contributor.laitosLiikuntatieteellinen tiedekuntafi
dc.contributor.laitosFaculty of Sport and Health Sciencesen
dc.contributor.oppiaineBiomekaniikkafi
dc.contributor.oppiaineGerontologian tutkimuskeskusfi
dc.contributor.oppiaineHyvinvoinnin tutkimuksen yhteisöfi
dc.contributor.oppiaineBiomechanicsen
dc.contributor.oppiaineGerontology Research Centeren
dc.contributor.oppiaineSchool of Wellbeingen
dc.type.urihttp://purl.org/eprint/type/JournalArticle
dc.date.updated2019-07-16T12:15:16Z
dc.type.coarhttp://purl.org/coar/resource_type/c_2df8fbb1
dc.description.reviewstatuspeerReviewed
dc.format.pagerange367-375
dc.relation.issn8756-3282
dc.relation.numberinseries0
dc.relation.volume127
dc.type.versionacceptedVersion
dc.rights.copyright© 2019 Elsevier Inc
dc.rights.accesslevelopenAccessfi
dc.type.publicationarticle
dc.subject.ysoeturauhassyöpä
dc.subject.ysohormonihoito
dc.subject.ysoluukudokset
dc.subject.ysoluuntiheys
dc.subject.ysosyöpähoidot
dc.format.contentfulltext
jyx.subject.urihttp://www.yso.fi/onto/yso/p14843
jyx.subject.urihttp://www.yso.fi/onto/yso/p980
jyx.subject.urihttp://www.yso.fi/onto/yso/p24381
jyx.subject.urihttp://www.yso.fi/onto/yso/p22879
jyx.subject.urihttp://www.yso.fi/onto/yso/p27422
dc.rights.urlhttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.relation.doi10.1016/j.bone.2019.06.005
jyx.fundinginformationThis research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
dc.type.okmA1


Aineistoon kuuluvat tiedostot

Thumbnail

Aineisto kuuluu seuraaviin kokoelmiin

Näytä suppeat kuvailutiedot

CC BY-NC-ND 4.0
Ellei muuten mainita, aineiston lisenssi on CC BY-NC-ND 4.0